abstract To determine whether protein tyrosine kinase (PTK) modulates volume-sensitive chloride current (I Cl.vol ) in human atrial myocytes and to identify the PTKs involved, we studied the effects of broad-spectrum and selective PTK inhibitors and the protein tyrosine phosphatase (PTP) inhibitor orthovanadate (VO 4 Ϫ 3 ). I Cl.vol evoked by hyposmotic bath solution (0.6-times isosmotic, 0.6T) was enhanced by genistein, a broad-spectrum PTK inhibitor, in a concentration-dependent manner (EC 50 ϭ 22.4 M); 100 M genistein stimulated I Cl.vol by 122.4 Ϯ 10.6%. The genistein-stimulated current was inhibited by DIDS (4,4 Ј -diisothiocyanostilbene-2,2 Ј -disulfonic acid, 150 M) and tamoxifen (20 M), blockers of I Cl.vol . Moreover, the current augmented by genistein was volume dependent; it was abolished by hyperosmotic shrinkage in 1.4T, and genistein did not activate Cl Ϫ current in 1T. In contrast to the stimulatory effects of genistein, 100 M tyrphostin A23 (AG 18) and A25 (AG 82) inhibited I Cl.vol by 38.2 Ϯ 4.9% and 40.9 Ϯ 3.4%, respectively. The inactive analogs, daidzein and tyrphostin A63 (AG 43), did not alter I Cl.vol . In addition, the PTP inhibitor VO 4 Ϫ 3 (1 mM) reduced I Cl.vol by 53.5 Ϯ 4.5% (IC 50 ϭ 249.6 M). Pretreatment with VO 4 Ϫ 3 antagonized genistein-induced augmentation and A23-or A25-induced suppression of I Cl.vol . Furthermore, the selective Src-family PTK inhibitor PP2 (5 M) stimulated I Cl.vol , mimicking genistein, whereas the selective EGFR (ErbB-1) kinase inhibitor tyrphostin B56 (AG 556, 25 M) reduced I Cl.vol , mimicking A23 and A25. The effects of both PP2 and B56 also were substantially antagonized by pretreatment with VO 4 Ϫ 3 . The results suggest that I Cl.vol is regulated in part by the balance between PTK and PTP activity. Regulation is complex, however. Src and EGFR kinases, distinct soluble and receptor-mediated PTK families, have opposing effects on I Cl.vol , and multiple target proteins are likely to be involved. A volume-sensitive chloride current, termed I C1.vol or I Cl,swell , is found in mammalian cardiac myocytes, including those from man (for reviews see Hiraoka et al., 1998; Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) . The current is activated by cell swelling and/or membrane deformation. I Cl.vol regulates cell volume (Suleymanian et al., 1995), shortens action potential duration (Vandenberg et al., 1997) , and depolarizes resting membrane potential (Du and Sorota, 1997), suggesting that I Cl.vol may play a role in cardiac electrophysiology and arrhythmogenesis in situ (Hiraoka et al., 1998) .
I N T R O D U C T I O N
A volume-sensitive chloride current, termed I C1.vol or I Cl,swell , is found in mammalian cardiac myocytes, including those from man (for reviews see Hiraoka et al., 1998; Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) . The current is activated by cell swelling and/or membrane deformation. I Cl.vol regulates cell volume (Suleymanian et al., 1995) , shortens action potential duration (Vandenberg et al., 1997) , and depolarizes resting membrane potential (Du and Sorota, 1997) , suggesting that I Cl.vol may play a role in cardiac electrophysiology and arrhythmogenesis in situ (Hiraoka et al., 1998) .
Multiple signaling pathways have been postulated to control I Cl.vol in cardiac (Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) and noncardiac tissues (Nilius et al., 1997) . One of these, protein tyrosine kinase (PTK), is immediately activated upon myocyte swelling (Sadoshima et al., 1996) . Inhibitors of PTK, such as the isoflavone genistein (Akiyama and Ogawara, 1991) and several tyrphostins (Gazit et al., 1989) , and inhibitors of protein tyrosine phosphatase (PTP), such as orthovanadate (VO 4 Ϫ 3 ) (Gordon, 1991) , are widely used to identify regulation by tyrosine phosphorylation. Blocking PTKs with genistein inhibits I Cl.vol in dog atrial cells (Sorota, 1995) , calf pulmonary artery endothelial cells (Voets et al., 1998) , and rabbit ciliary epithelial cells (Shi et al., 2002) . On the other hand, PTP inhibitors also suppress I Cl.vol in bovine chromaffin cells (Doroshenko, 1998) and mouse L-fibroblasts (Thoroed et al., 1999) . These studies indicate that the phosphorylation and dephosphorylation of tyrosine are involved in the modulation of I Cl.vol . Manipulations with opposite consequences for tyrosine phosphorylation affected I Cl.vol identically, however, suggesting regulation may be tissue or species specific (Nilius et al., 1997; Okada, 1997) . Such diversity may arise because tyrosine phosphorylation by specific PTKs controls distinct signaling cascades (Hunter, 1995; Pawson and Scott, 1997; Zhang et al., 2002) . Moreover, PTK inhibitors previously have been shown to modulate both anion (Sorota, 1995; Gadsby and Nairn, 1999) and cation channels (Zhou et al., 1997) in heart and other tissues (Davis et al., 2001 ).
Although we (Li et al., 1996) and others (Oz and Sorota, 1995; Sakai et al., 1995; Sato and Koumi, 1998) identified I Cl.vol in human atrial myocytes, the modulation of I Cl.vol by signaling cascades is incompletely understood (Nilius et al., 1997; Sorota, 1999; Hume et al., 2000) and may be species and tissue dependent (Nilius et al., 1997; Okada, 1997) . The present study demonstrated that protein tyrosine phosphorylation and dephosphorylation regulate I Cl.vol in human atrial myocytes and that inhibition of Src family and epidermal growth factor receptor (EGFR, ErbB-1) tyrosine kinases have opposing effects.
M A T E R I A L S A N D M E T H O D S

Cell Isolation
Atrial myocytes were isolated from specimens of right atrial appendage obtained from patients (50.1 Ϯ 8.2-yr-old, range, 35-74) undergoing coronary artery bypass. Procedures for obtaining the tissue with the patients' written consent were approved by the Ethics Committee of the University of Hong Kong. No evidence for atrial arrhythmias or atrial dilation was found in any of the patients based on ECG and echocardiograms.
After excision, samples were quickly immersed in oxygenated, nominally Ca 2 ϩ -free cardioplegic solution for transport to the laboratory. Atrial myocytes were enzymatically dissociated by a technique modified from that described previously (Li et al., 1996) . Briefly, the myocardial tissue was sliced with a sharp blade, placed in a 15-ml tube containing 10 ml of Ca 2 ϩ -free Tyrode solution (36 Њ C), and gently agitated by continuous bubbling with 100% O 2 for 15 min with transfer to fresh solution after 5 min. Then, the chunks were incubated for 50 min in a similar solution containing 150-200 U/ml collagenase (CLS II, Worthington Biochemical), 1.2 U/ml protease (type XXIV, Sigma-Aldrich), and 1 mg/ml bovine serum albumin (Sigma-Aldrich). Finally, the tissue was reincubated in a fresh enzyme solution without protease. The number and the quality of the isolated cells were determined by microscopic examination at 5-10-min intervals. When the yield appeared to be maximal, the tissue was suspended in a high K ϩ medium and gently pipetted. The isolated myocytes were kept at room temperature in the high K ϩ medium for at least 1 h before study.
A small aliquot of the solution containing the isolated cells was placed in an open perfusion chamber (1 ml) mounted on the stage of an inverted microscope (Leica DM IL). Myocytes were allowed to adhere to the bottom of the chamber for 5-10 min, and were then superfused at 2-3 ml/min with isosmotic 1.0T (T, times isosmotic), hyposmotic 0.6T or hyperosmotic 1.4T Tyrode solution. Only quiescent rod-shaped cells showing clear cross-striations were used.
Solution and Drugs
Ca 2 ϩ -free cardioplegic solution for specimen transport contained (in mM): 50 KH 2 PO 4 , 8 MgSO 4 , 5 adenosine, 10 HEPES, 140 glucose, 100 mannitol, 10 taurine, pH was adjusted to 7.3 with KOH. Standard Tyrode solution contained: 140 NaCl, 5.4 KCl, 1 MgCl 2 , 1.8 CaCl 2 , 0.33 NaH 2 PO 4 , 5 HEPES, 10 glucose, pH adjusted to 7.4 with NaOH. Ca 2 ϩ was omitted from the Tyrode solutions used for enzymatic digestion and for washing the sliced atrial tissue. For osmotic swelling experiments, hyposmotic 0.6T ( ‫ف‬ 180 mosmol/L) Tyrode was made by reducing NaCl from 140 to 80 mM, and isosmotic 1T ( ‫ف‬ 300 mosmol/L) and hyperosmotic 1.4T ( ‫ف‬ 420 mosmol/L) Tyrode were prepared by adding 125 or 240 mM mannitol, respectively, to 0.6T. The pipette solution contained: 20 CsCl, 110 Cs-aspartate, 1.0 MgCl 2 , 10 HEPES, 5 EGTA, 0.1 GTP, 5 Na 2 -phosphocreatine, and 5 Mg-ATP, pH adjusted to 7.2 with CsOH ( ‫ف‬ 295 mosmol/L). The high K ϩ storage medium contained: 10 KCl, 120 K-glutamate, 10 KH 2 PO 4 , 1.8 MgSO 4 , 10 taurine, 10 HEPES, 0.5 EGTA, 20 glucose, 10 mannitol 10, pH adjusted to 7.3 with KOH. All experiments were done at room temperature, 21-22 Њ C.
3-(4-Chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo [3,4-d] pyrimidin-4-amine (PP2) was purchased from Tocris. All other reagents were obtained from Sigma-Aldrich. Stock solutions were made with DMSO for genistein (100-200 mM), daidzein (100 mM), tyrphostin A23 (AG 18), A25 (AG 82), A63 (AG 43), B56 (AG 556) (100 mM), and tamoxifen (20 mM). The stocks were divided into aliquots and stored at Ϫ 20 Њ C. The maximum 0.1% final concentration of DMSO in bath solution did not affect I Cl.vol . Na 3 VO 4 stock solution (1 M) was made with distilled water. DIDS (4,4 Ј -diisothiocyanostilbene-2,2 Ј -disulfonic acid, 150 M) was freshly dissolved in the experimental solution.
Data Acquisition and Analysis
Whole-cell currents were recorded using an EPC-9 amplifier and Pulse software (Heka), and signals were low-pass filtered (2 kHz) before 5 kHz digitization. Pipette resistance was 2-3 M ⍀ , and gigaseals were Ͼ 10 G ⍀ . Series resistance (3-8 M ⍀ ) was compensated (60-80%) after membrane rupture, and a 3-M KCl-agar bridge was used as a reference electrode. In separate experiments, the liquid junction potential (bath Ϫ pipette) was measured as ϩ 12 mV and was not corrected.
Relative cell volume was determined during the whole-cell recording using each cell as its own control (Drewnowska and Baumgarten, 1991) . Images of myocytes were captured with a digital camera (Leica DC300) at selected time points during the experiment. Cell area and width were measured with commercial software (Optimas, Media Cybernetics). Changes in cell width and thickness are proportional. Taking each cell as its own control, relative cell volume was calculated as vol t /vol c ϭ 100 ϫ (area t ϫ width t )/(area c ϫ width c ), where t and c refer to test (e.g., 0.6T) and control (1T) solutions, respectively, and is expressed as a percentage. The calculated values are independent of assumptions regarding the geometric shape of the cross section of the myocyte as long as the shape does not change. These methods provide estimates of relative cell volume that are reproducible to Ͻ 1% (Drewnowska and Baumgarten, 1991) .
Nonlinear curve fitting was performed using Pulsefit 8.53 (Heka) and SigmaPlot 8.01 (SPSS). Paired or unpaired Student's t tests were used as appropriate to evaluate differences between two groups, and ANOVA was used for multiple groups (Sigma-Stat 2.03, SPSS). P Ͻ 0.05 was considered to indicate statistical significance. Results are presented as mean Ϯ SE.
R E S U L T S
Osmotic Swelling-induced Current Fig. 1 A illustrates the time-course of swelling-induced changes in membrane current at ϩ50 mV in a human atrial myocyte when bath solution was switched from isosmotic 1T to hyposmotic 0.6T solution and then back to 1T. Membrane current in 0.6T gradually increased to a new steady-state within 15 min and fully returned to control levels after reexposure to 1T. Similar results were obtained in five cells. The swelling-induced current is I Cl.vol , as described previously (Li et al., 1996) . This was confirmed by the application the I Cl.vol blocker DIDS (Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) . Fig. 1 B displays currents elicited by voltage steps to between Ϫ100 and ϩ60 mV from Ϫ40 mV in 1T, 0.6T, and 0.6T with 150 M DIDS for 8 min, and Fig. 1 C shows the I-V relationships for the swelling-induced current before and after exposure to DIDS (n ϭ 6). The swelling-induced current outwardly rectified and reversed at Ϫ28 mV (Ϫ40 mV after correction for the liquid junction potential), near the predicted E Cl , Ϫ35 mV. DIDS almost completely inhibited the outward current, whereas inward current was inhibited by ‫.%05ف‬ These are characteristics of I Cl.vol and its voltage-dependent block by DIDS (Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) . DIDS, a blocker of I Cl.vol , substantially inhibited the swellinginduced current. Arrows indicate 0 current. Voltage protocol for B and C, 300-ms steps to between Ϫ100 and ϩ60 mV from Ϫ40 mV (inset). (C) Current-voltage (I-V) relationships for 0.6T-induced current (᭺) and 0.6T-induced current with 150 M DIDS (᭹); difference currents were obtained by subtracting the current in 1T from that in 0.6T and 0.6T with DIDS. The 0.6T-induced current was outwardly rectifying and was significantly inhibited by DIDS at test potentials from Ϫ100 to Ϫ50 mV and from Ϫ20 to ϩ60 mV (n ϭ 6, P Ͻ 0.05 or P Ͻ 0.01). Block by DIDS was greater at positive than negative voltages, as expected for I Cl.vol . 
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Modulation of Cardiac I Cl.vol by Tyrosine Kinases
Effects of Genistein on I Cl.vol To study the effects of PTKs on I Cl.vol , the broad-spectrum PTK blocker genistein was applied after activating I Cl.vol by osmotic swelling. Fig. 2 A shows the time-course of current at ϩ50 mV as bathing solution was switched from 1T, to 0.6T, and to 0.6T with 100 M genistein. I Cl.vol in 0.6T was significantly enhanced by genistein, and the stimulation was completely reversed upon washout. Similar results were obtained in seven cells. Families of currents obtained between Ϫ100 and ϩ60 mV under the same conditions are presented in Fig. 2 B. The I-V relationships showed that genistein reversibly increased the amplitude of outwardly rectifying I Cl.vol in 0.6T at test potentials from Ϫ100 to Ϫ50 mV and from ϩ10 to ϩ60 mV (Fig. 2 C ; P Ͻ 0.05 or P Ͻ 0.01, n ϭ 7).
The concentration-response relationship for stimulation of I Cl.vol by genistein in 0.6T was evaluated at ϩ50 mV (Fig. 2 D) . Data were fitted with the equation:
, where E is the stimulation of I Cl.vol in percent at concentration C, E max is the maximum stimulation, EC 50 is the concentration for half-maximum action, and b is the Hill coefficient. The best-fit parameters were E max ϭ 134.4%, EC 50 ϭ 22.4 M, and b ϭ 1.37.
To rule out possible nonspecific effects of genistein, daidzein, an analogue of genistein that does not inhibit PTK, was studied in five myocytes. Fig. 3 shows that daidzein (100 M) did not affect the magnitude or the time-independence of the current at ϩ50 mV, whereas genistein (100 M) reversibly stimulated the current by Ͼ60% in the same myocyte. I-V relationships confirmed that daidzein did not affect I Cl.vol over the entire voltage range examined (Fig. 3 C) even though genistein enhanced the current in each cell studied.
Effects of I Cl.vol Blockers and Cell Volume on Genistein-enhanced Current
To verify the identity of the genistein-induced increase of Cl Ϫ current, DIDS and tamoxifen, which block I Cl.vol but not I Cl.cAMP in heart (Vandenberg et al., 1994; Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) , were used. Currents were recorded in 1T, after swelling in 0.6T, after stimulation of current by 100 M genistein in 0.6T reached a steady-state, and after exposure to I Cl.vol blockers in 0.6T in the continued presence of genistein. At ϩ50 mV, DIDS (150 M) decreased the I Cl.vol by 91.2 Ϯ 2.3% (n ϭ 4, unpublished data). In addition, tamoxifen (20 M) blocked ‫%59ف‬ of the current at ϩ 50 mV (n ϭ 3) in the continued presence of genistein (Fig. 4) . Thus, two structural distinct I Cl.vol blockers inhibited both the current augmented by genistein and the current activated by cell swelling.
Another means of identifying the genistein-augmented current is to examine its dependence on cell volume. Genistein (100 M) did not alter membrane conductance when it was applied in 1T (n ϭ 5, unpublished data). Furthermore, both the 0.6T-and genistein-dependent activation of current promptly was reversed by cell shrinkage in 1.4T in the continued presence of genistein (Fig. 5) . Together, these data indicate that genistein modulates a Cl Ϫ current that is turned on in swollen myocytes and turned off by cell shrinkage.
Effect of Orthovanadate on I Cl.vol
The PTP inhibitor VO 4 Ϫ3 was used to determine whether tyrosine dephosphorylation is involved in the activation of I Cl.vol in human atrial myocytes. Fig. 6 A shows that VO 4 Ϫ3 (1 mM) substantially inhibited I Cl.vol in 0.6T within 5 min, and the effect rapidly and fully reversed on washout. I-V relationships in the absence and presence of VO 4 Ϫ3 indicated that the current blocked by VO 4 Ϫ3 was outwardly rectifying and reversed near the reversal potential for I Cl.vol (Fig. 6 B; n ϭ 7). In contrast, VO 4 Ϫ3 (1 mM) did not alter currents in 1T, confirming that the VO 4 Ϫ3 -sensitive current was I Cl.vol (n ϭ 5; unpublished data).
The concentration-response relationship for block of I Cl.vol by VO 4 Ϫ3 at ϩ50 mV is displayed in Fig. 6 C. Data were fitted as described above, except for inhibition. The best-fit parameters were E max ϭ 49.5%, IC 50 ϭ 249.6 M, and b ϭ 1.71.
Influence of Orthovanadate on Genistein
If stimulation of I Cl.vol by genistein is due to block of tyrosine phosphorylation, inhibiting PTP-dependent tyrosine dephosphorylation should antagonize its effect. A test of this prediction is illustrated in Fig. 7 A. At ϩ50 mV, VO 4 Ϫ3 significantly reduced I Cl.vol in 0.6T and substantially prevented stimulation of I Cl.vol by genistein. Ϫ3 significantly antagonized the genistein-induced increase of I Cl.vol over the entire voltage range studied as compared with genistein alone (see Fig. 2 ). The results suggest that regulation of I Cl.vol depends at least in part on the balance of tyrosine phosphorylation by PTKs and dephosphorylation by PTPs. Both genistein-and osmotic swelling-induced stimulation of I Cl.vol were opposed by blocking dephosphorylation of tyrosine.
Selective Inhibition of Src
Although genistein is a broad-spectrum PTK inhibitor that blocks both receptor and nonreceptor PTK, its ED 50 for stimulation of I Cl.vol , 22.4 M (see Fig. 2 D) was almost identical to its IC 50 for block of pp60 v-src , 25.9 or 29.6 M ( Akiyama and Ogawara, 1991) . This suggested that inhibition of Src family PTKs might be responsible the stimulation of I Cl.vol . To test this hypothesis, we used PP2, a selective inhibitor of Src family PTKs (Hanke et al., 1996) . Fig. 8 A shows I Cl.vol in 0.6T before and after application of 5 M PP2 and after its washout. PP2 gradually increased I Cl.vol , reaching a steady-state after 10 min, and nearly complete recovery was obtained after a prolonged (Ͼ30 min) washout of the drug. As previously shown for genistein (Fig. 6) , stimulation of I Cl.vol by PP2 was antagonized by pretreatment with VO 4 -3 (Fig. 8 B) . At ϩ50 mV, for example, PP2 increased I Cl.vol by 67.5 Ϯ 15.2% (n ϭ 9, P Ͻ 0.01), whereas stimulation Ϫ3 significantly reduced stimulation of I Cl.vol by genistein (compare with Fig. 2 ; P Ͻ 0.01), a small but significant stimulation was observed, 16.9 Ϯ 2.5 and 18.9 Ϯ 4.7% at Ϫ90 and ϩ50 mV (P Ͻ 0.01, n ϭ 7). Voltage protocols are shown in insets. by PP2 was not significant, 2.2 Ϯ 7.1% (n ϭ 7, ns), after pretreatment with 1 mM VO 4 -3 (Fig. 8 C) . These results suggest that Src family PTKs play a role in the modulation of I Cl.vol in human atrial myocytes.
Effect of Tyrphostins on I Cl.vol
Another important class of PTK inhibitors is the tyrphostins. To study effects of these nonisoflavone PTK inhibitors on I Cl.vol , tyrphostin A23 (100 M) was applied after activation of I Cl.vol in 0.6T. In contrast to the stimulatory effect of genistein and PP2, A23 reversibly inhibited I Cl.vol (Fig. 9 A) . I-V relationships show that A23 significantly decreased the amplitude of I Cl.vol at test potentials from Ϫ100 to Ϫ50 mV and 0 to ϩ60 mV (n ϭ 7, P Ͻ 0.05 or P Ͻ 0.01; Fig. 9 B) . The concentration-response relationship for inhibition of I Cl.vol by A23 in 0.6T was evaluated at ϩ50 mV (Fig. 9 C) . Data were fitted with the Hill equation, and the concentration for half maximum inhibition (IC 50 ) of I Cl.vol was 27.5 M, and the Hill coefficient was 0.71.
Another tyrphostin compound, A25, produced a similar inhibition of I Cl.vol as A23 (n ϭ 6, unpublished data). To confirm the tyrphostin-sensitive currents were volume sensitive, A23 and A25 were studied in 1T. No change in currents was observed (100 M, n ϭ 4 each; unpublished data). Thus, tyrphostin PTK inhibitors, which are structurally distinct from genistein and PP2, produce the opposite effect on I Cl.vol .
Tyrphostin A63, an inactive analogue of A23 and A25, was examined to exclude nonspecific effects of tyrphostins on I Cl.vol . I Cl.vol was not affected by the application of 100 M A63 for 8 min but was substantially reduced by 100 M A23 in the same cell (Fig. 10, A and  B) . The I-V relationships confirmed that A63 did not alter I Cl.vol over the entire voltage range studied (Fig. 10  C; n ϭ 5). The results suggest that suppression of I Cl.vol by tyrphostin A23 and A25 was related to inhibition of tyrphostin-sensitive PTKs.
Influence of Orthovanadate on Tyrphostins
The effect of block of PTP on the modulation I Cl.vol by tyrphostin A23 is illustrated in Fig. 11 . As shown previously (Fig. 6) , VO 4 Ϫ3 (1 mM) substantially inhibited I Cl.vol at ϩ50 mV in 0.6T. After block of PTP by VO 4 Ϫ3 , A23 (100 M; Fig. 10 A) caused only a slight further suppression of I Cl.vol . Fig. 11 C summarizes the data for A23. I Cl.vol was inhibited 38.3 Ϯ 4.2% by A23 (n ϭ 7, P Ͻ 0.01; data from Fig. 9 C) , whereas 1 mM VO 4 Ϫ3 inhibited I Cl.vol by 48.0 Ϯ 5.9% (n ϭ 6, P Ͻ 0.01). After pretreatment with VO 4 Ϫ3 , A23 produced only a slight, 11.1 Ϯ 4.3%, but significant further decrease of I Cl.vol (P Ͻ 0.05, n ϭ 6). Thus, inhibition of I Cl.vol by A23 was significantly precluded by pretreatment with VO 4 Ϫ3 (P Ͻ 0.01). Similarly, A25 inhibited I Cl.vol by 41.0 Ϯ 3.4% (n ϭ 6, P Ͻ 0.01), whereas after pretreatment with VO 4 -3 , A25 decreased I Cl.vol by only an additional 14.3 Ϯ 3.4% (n ϭ 6, P Ͻ 0.05). Thus, the inhibitory effect of A25 also was significantly precluded by VO 4 Ϫ3 (P Ͻ 0.01). The results suggest that the inhibition of I Cl.vol by A23 and A25 depend on the balance between tyrosine phosphorylation and dephosphorylation.
Effects of Receptor-mediated PTK Inhibition on I Cl.vol
Tyrphostin A23 and A25 are considered broad-spectrum PTK inhibitors, as is genistein, although potency of these agents for specific PTKs varies. For example, A23 is a more potent blocker of EGFR (ErbB-1) kinase than of Src (Ramdas et al., 1994) . This and the previous results implicating Src in the stimulation of I Cl.vol suggested that inhibition of I Cl.vol might be due to a receptor-mediated PTK such as EGFR kinase. To test this hypothesis, we used tyrphostin B56 (AG 556), a highly selective inhibitor of EGFR kinase that does not block Src family PTK (Gazit et al., 1991; Brenner et al., 1998) . Fig. 12 shows the effect of B56 at 10 M on I Cl.vol in 0.6T. B56 reversibly suppressed I Cl.vol (Fig. 12 A) . Pretreatment with 1 mM VO 4 Ϫ3 largely precluded a further inhibition of I Cl.vol by B56 (Fig. 12 B) . Fig. 12 C summarizes the data for B56 at ϩ50 mV. I Cl.vol was inhibited 72.6 Ϯ 3.1% by B56 (n ϭ 8, P Ͻ 0.01), whereas 1 mM VO 4 Ϫ3 inhibited I Cl.vol by 45.6 Ϯ 5.7% (n ϭ 9, P Ͻ 0.01). After pretreatment with VO 4 Ϫ3 , B56 produced a slight but significant further inhibition of I Cl.vol , 9.9 Ϯ 5.3% of I Cl.vol in 0.6T (P Ͻ 0.05 vs. after VO 4 Ϫ3 , n ϭ 9). The percent reduction of I Cl.vol by VO 4 Ϫ3 plus B56, 54.4 Ϯ 6.5%, was less than that with B56 alone, 72.6 Ϯ 3.1% (P Ͻ 0.01). Thus, selective inhibition of EGRF kinase by B56 and its interaction with VO 4 Ϫ3 recapitulated the observations made with the broad-spectrum tyrphostins, A23 and A25.
Relative Cell Volume
To quantify the swelling of human atrial myocyte under the present experimental conditions, relative cell volume was determined using each cell as its own control while the cell was voltage clamped. Relative cell volume increased in 0.6T to 132.4 Ϯ 2.5% of that in 1T (n ϭ 25). Although genistein, VO 4 Ϫ3 , and tyrphostin A23 and A25 substantially modulated I Cl.vol , they did not significantly affect relative cell volume. Relative cell volume was 134.3 Ϯ 3.4, 131.7 Ϯ 8.3, 133.6 Ϯ 5.7, and 135.6 Ϯ 4.2%, respectively, in the presence of 100 M genistein, A23, or A25 or 1 mM VO 4 Ϫ3 (n ϭ 4-7; P ϭ NS vs. 0.6T).
D I S C U S S I O N
This study provides the first evidence that I Cl.vol in human atrial myocytes is regulated in part by the interplay of PTK and PTP and that Src and EGFR kinases, distinct PTK families, have opposing effects I Cl.vol . I Cl.vol was enhanced by the broad-spectrum isoflavone PTK inhibitor genistein and the selective Src family inhibitor PP2, whereas broad-spectrum tyrphostin PTK inhibitors A23 and A25, and the highly selective EGFR kinase inhibitor B56 diminished I Cl.vol . I Cl.vol also was suppressed by the PTP inhibitor VO 4 Ϫ3 . Observations that isoflavone and tyrphostin PTK inhibitors modulate I Cl.vol in opposite directions imply that more than one PTK and more than one tyrosine phosphorylation site contributes to regulation of I Cl.vol . Moreover, genistein did not stimulate I Cl.vol in isosmotic 1T solution and did not maintain the current after osmotic shrinkage in 1.4T. This suggests that tyrosine phosphorylation modulates the effects of other signaling cascades rather than directly controlling channel gating. Src and EGFR kinase are well placed to be sensors of cell volume and mechanical stretch. These signaling molecules interact with cytoskeleton, integral membrane proteins, and the sarcolemma, and tyrosine phosphorylation is among the earliest responses to osmotic swelling in cardiac myocytes (Sadoshima et al., 1996) and other cells (Tilly et al., 1993) . Genistein, tyrphostins, and VO 4 Ϫ3 are widely employed to ascertain whether PTKs and PTPs participate in signaling cascades, but these agents also might act by nonspecific mechanisms (Davis et al., 2001) . Two lines of evidence support the conclusion that PTK and PTP inhibitors acted via phosphotyrosine in this study. First, daidzein and tyrphostin A63, inactive analogs of genistein and tyrphostins, respectively, were without effect. Second, as expected for phosphorylation-dependent processes, inhibition of PTP by VO 4 Ϫ3 countered inhibition of PTK. This observation makes it unlikely that genistein acted directly on the I Cl.vol channel, for example, by altering its volume set point. Alternatively, one might argue that the tyrphostins A23, A25, and B56 act as antioxidants (Sagara et al., 2002) rather than PTK inhibitors. The antioxidant hypothesis does not explain why VO 4 Ϫ3 suppressed the action of tyrphostins, however. One also might posit that the VO 4
Ϫ3
anion suppressed I Cl.vol (e.g., Fig. 6 ) by blocking the Cl Ϫ channel directly. This idea seems unlikely because the fractional block of Cl Ϫ current by VO 4 -3 strongly depended on experimental conditions (1T vs. 0.6T; stimulated by genistein or PP2 vs. inhibited by tyrphostin A23, A25, or B56); if VO 4 Ϫ3 simply blocked the pore, fractional block should have been independent of interventions that increased or decreased I Cl.vol . Moreover, block by VO 4 Ϫ3 did not appear to be voltage dependent. On the other hand, because of its high affinity for phosphate binding sites, VO 4 Ϫ3 interferes with several phosphorylation-dependent processes besides PTP. The possibility that nonspecific effects of PTK inhibitors and VO 4 Ϫ3 contributed to the results cannot be rigorously excluded.
Another concern is that genistein augments I Cl,cAMP , the CFTR current, in heart, cell lines, and expression systems (Shuba et al., 1996; Zhou et al., 1998; Gadsby and Nairn, 1999) . This raises a question about the origin of the genistein-stimulated current. Identification of I Cl.vol was based on biophysical and pharmacological criteria, including outward rectification, volume sensitivity, reversal potential, and inhibition by DIDS and tamoxifen, blockers of I Cl.vol (Vandenberg et al., 1994; Sorota, 1999; Hume et al., 2000; Baumgarten and Clemo, 2003) . I Cl,cAMP can be confused with I Cl.vol in certain situations but was ruled out here; cardiac I Cl,cAMP is insensitive to both DIDS and tamoxifen (Vandenberg et al., 1994; Hume et al., 2000; Baumgarten and Clemo, 2003) . Most workers agree that I Cl,cAMP is not detectable in human atrial myocytes (Oz and Sorota, 1995; Sakai et al., 1995; Li et al., 1996; Sato and Koumi, 1998) , although one group reported I Cl,cAMP in a fraction (Ͻ20%) of human atrial cells and coexpression of exon 5ϩ and 5Ϫ splice variants of CFTR (Warth et al., 1996) . Moreover, genistein could not stimulate membrane current under 1T conditions. Finally, contrary to the present results, stimulation of I Cl,cAMP by genistein is not reversed by inhibiting PTP (Zhou et al., 1998; Gadsby and Nairn, 1999) . The Ca 2ϩ -activated Cl Ϫ cur- rent, I Cl,Ca (Hiraoka et al., 1998; Sorota, 1999; Hume et al., 2000) , also is unlikely to be responsible for the present observations; it is a transient current and intracellular Ca 2ϩ was well buffered here. Regulation of I Cl.vol by genistein-sensitive PTKs appears to be different in human atrial than in canine atrial and rabbit ventricular myocytes. Sorota (1995) reported that I Cl.vol was inhibited by pretreatment with 50-80 M genistein and that acute application of tyrphostin A51, an EGFR kinase inhibitor, and herbimycin A, a Src inhibitor, had no effect. I Cl.vol activated by mechanical stretch also was suppressed by the acute application of 100 M genistein or 10 M PP2 (Browe and Baumgarten, 2003) . It remains unclear, however, whether these apparent differences in the regulation of I Cl.vol arise from the intrinsic characteristics of the cells studied or experimental details such as the timing of genistein exposure, means of activating I Cl.vol , or temperature at which the study was done. Furthermore, enhancement of 125 I Ϫ efflux in cultured neonatal rat myocytes by pervanadate has been attributed to inhibition of PTP and activation of I Cl.vol (Tilly et al., 1996) , but the efflux pathway was not identified by direct means.
Control of I Cl.vol by Tyrosine Phosphorylation in Human Atria
The simplest explanation for the actions of genistein, PP2, VO 4 Ϫ3 , and their interactions is that dephosphorylation of a critical tyrosine residue on the channel or a signaling molecule directly or indirectly augments I Cl.vol . In this model (Fig. 13) , inhibition of Src family PTK by genistein or PP2 allows unopposed dephosphorylation of a tyrosine (Tyr1) by PTP, whereas inhibition of PTP blocks I Cl.vol by allowing its unopposed phosphorylation by the same PTK. This also explains why pretreatment with VO 4 Ϫ3 precluded the effect of genistein and PP2. Once Tyr1 becomes phosphorylated during VO 4 Ϫ3 pretreatment, blocking PTKs will have little effect because there is no efficient means of dephosphorylating the residue. It is important to note, however, that genistein did not stimulate I Cl.vol in 1T, and stimulation of I Cl.vol was reversed by osmotic shrinkage in 1.4T. Thus, phosphorylation of the genistein-sensitive site by Src does not appear to be sufficient to activate or maintain I Cl.vol in the face of contrary cell volume-dependent signaling. Such volume-dependent signaling has been postulated to include one or more Ser/Thr kinases (PKC, PKA, and MAPK) and phosphatases (Nilius et al., 1997; Sorota, 1999; Hume et al., 2000) , and the activity of Ser/Thr kinases and phosphatases are modulated by tyrosine phosphorylation (Hunter, 1995; Pawson and Scott, 1997; Zhang et al., 2002) .
A second tyrphostin-sensitive PTK and a second phosphorylation site, Tyr2 (Fig. 13) , also must be present and regulate I Cl.vol in the opposite manner as Tyr1 because I Cl.vol was inhibited when EGFR kinase was blocked by tyrphostin B56, A23, or A25. Recently, activation of I Cl.vol by EGF peptides and inhibition by tyrphostin B46, an inhibitor of EGFR tyrosine kinase, was reported in murine mammary C127 cells (Abdullaev et al., 2003) . The proposed involvement of EGFR kinase in the regulation of cardiac I Cl.vol does not necessarily require the presence of its ligand, however. Transactivation of EGFR in myocytes and other types of cell can be accomplished by multiple signaling molecules, oxidants, and hyperosmotic shock (Zwick et al., 1999; Shah and Catt, 2003) . Moreover, EGFR activity is regulated by autophosphorylation and Src-dependent tyrosine phosphorylation, and Src may act directly on EGFR and downstream. Opposing effects of specific PTK families on molecular and cellular function is a known regulatory motif (Pawson and Scott, 1997; Yoon et al., 1998; Zhang et al., 2002) , but such dual regulation has not been reported previously for I Cl.vol or other channels (Davis et al., 2001) .
Although both Src and EGFR kinases regulate I Cl.vol , control by Src appeared to be dominant under present conditions. The net effect of inhibiting PTP with VO 4 Ϫ3 Figure 13 . Schematic model of biphasic regulation of I Cl.vol by Src family and EGFR PTKs and PTPs. Two tyrosine phosphorylation sites, Tyr 1 and Tyr 2, on the I Cl.vol channel or signaling molecules are postulated. Tyr1 is phosphorylated by a PP2-and genistein-sensitive Src family kinase and dephosphorylated by a VO 4 Ϫ3 -sensitive PTP (PTP a ). Phosphorylation of Tyr1 by one or more steps (dashed line) favors I Cl.vol channel closure, whereas dephosphorylation favors opening. Tyr2 is phosphorylated by tyrphostin-sensitive EGFR kinase and dephosphorylated by a VO 4 Ϫ3 -sensitive PTP (PTP b ). In contrast to Tyr1, phosphorylation of Tyr2 favors channel opening, whereas dephosphorylation favors closure. The effect of VO 4 Ϫ3 on Tyr1 (thick lines) was dominant over that on Tyr2 (thin lines). On the other hand, genistein did not activate I Cl.vol in 1T or maintain its activation after osmotic shrinkage (thick solid lines). Therefore, tyrosine phosphorylation appears to modulate channel activity rather than directly control gating.
was suppression of current, as expected from phosphorylation of Tyr1, rather than the stimulation expected from phosphorylation of Tyr2. The outcome of inhibiting PTPs with opposing actions might reflect differing sensitivities of two PTPs to VO 4 Ϫ3 , differing basal activities of Src and EGFR kinase, or the functional consequences of phosphorylation at Tyr1 and Tyr2 and their position in the signaling cascade. The effect of temperature (21-22ЊC) on the balance between these PTKs was not evaluated. Finally, our simplified model assumes that inhibition of PTKs and PTPs are independent. To the contrary, PTK positively regulates PTP and PTP negatively regulates PTK in certain cases Vogel et al., 1993) .
Although genistein and both tyrphostin A23 and A25 are considered broad-spectrum PTK inhibitors, details of their pharmacology support the conclusions reached with the specific PTK inibitors, PP2 and B56. Genistein binds to the ATP site on PTK and blocks pp60 v-src with an IC 50 of 25.9 or 29.6 M ( Akiyama and Ogawara, 1991) . This is in good agreement with the EC 50 , 22.4 M, for genistein-dependent stimulation of I Cl.vol , and 100 M genistein should substantially inhibit Src. This notion is supported by the results with the Src family PTK inhibitor PP2. On the other hand, A23 and A25 bind to the substrate site (Gazit et al., 1989) and block Src with IC 50 s of 440 and 150 M, respectively (Ramdas et al., 1994) . Thus, only partial inhibition of Src should have occurred with the 100 M tyrphostin A23 or A25 used here.
Regulation of I Cl.vol by Tyrosine Phosphorylation in Other Tissues
Consistent with the present results with genistein and VO 4 Ϫ3 , inhibition of PTP, which favors tyrosine phosphorylation, blocks swelling-induced activation of I Cl.vol in bovine chromaffin cells (Doroshenko, 1998) and mouse L-fibroblasts (Thoroed et al., 1999) . Genistein and tyrphostin B46 do not alter I Cl.vol in chromaffin cells, however (Doroshenko, 1998) .
Evidence in several systems indicates tyrosine phosphorylation can stimulate I Cl.vol . Expression of p56 lck , an Src family PTK, was sufficient to activate I Cl.vol in human T lymphocytes in the absence of swelling (Lepple-Wienhues et al., 1998) . In ciliary epithelial cells, swellinginduced I Cl.vol was augmented by a peptide that binds to the SH2 domain and up-regulates c-Src (Shi et al., 2002) . Moreover, PTK inhibitors suppress and PTP inhibitors stimulate I Cl.vol in calf pulmonary artery endothelial (Voets et al., 1998) and human prostate cancer epithelial cells (Shuba et al., 2000) . Finally, genistein also blocks I Cl.vol in rat astrocytes (Crepel et al., 1998) .
Significance
Regulation of I Cl.vol by phosphorylation is variously reported to depend on PKC, PKA, PTK, and MAPK in different cell types and species (Nilius et al., 1997; Sorota, 1999; Hume et al., 2000) . Involvement of PTK was first proposed based on 125 I Ϫ flux studies in human intestinal 407 cells (Tilly et al., 1993) , and the present studies establish the importance of tyrosine phosphorylation in this process in human atrial cells. There are multiple sites of cross-talk between PTKs and PTPs and the PKC, PKA, and MAPK cascades (Baumgarten and Clemo, 2003) , and each will need to be explored to fully understand the regulation of I Cl.vol in heart.
Both the molecular identity of I Cl.vol and the signaling systems responsible for its control are controversial (Nilius et al., 1997; Okada, 1997; Sorota, 1999; Hume et al., 2000; Jentsch et al., 2002) . Some of the conflicts in the literature might be rationalized if multiple distinct molecules produce the current empirically defined as I Cl.vol or if the volume sensor or regulatory signaling cascades are tissue or species specific. Evidence for the participation of multiple pore-forming molecules includes the widely varying unitary conductance of swelling-activated Cl Ϫ channels; unitary conductance is 9.6 pS in human prostate (Shuba et al., 2000) , 31 pS in lymphocytes (Lepple-Wienhues et al., 1998) , and 105 pS in ciliary epithelium (Zhang and Jacob, 1997) . Moreover, multiple swelling activated unitary Cl Ϫ currents are present in several cells (Banderali and Ehrenfeld, 1996; Zhang and Jacob, 1997) . In rabbit atrial myocytes, a DIDS-sensitive, ‫-06ف‬pS outwardly rectifying channel was described (Duan and Nattel, 1994 ) and a 28-pS channel was observed in other experiments (Duan et al., 1997) . In contrast, an 8.6-pS DIDS-and stretch-sensitive Cl Ϫ channel was found in human atrial myocytes (Sato and Koumi, 1998) . Thus, it also is possible that multiple channel proteins controlled by distinct signaling pathways contribute to I Cl.vol in heart.
